ArticleAntimicrobial agents and chemotherapy2011
Efficacy of antimicrobial peptoids against Mycobacterium tuberculosis.
Article in Antimicrobial agents and chemotherapy, 2011. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 48 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
48 citing papers in PubMed.
- Recent progress in the structure-activity relationship of antibacterial peptoids.RSC advances · 2026Review
- A generalizable assay for intracellular accumulation to profile cytosolic drug delivery in mammalian cells.Communications chemistry · 2026Article
- Article
- Antiparasitic effect of peptoids againstMicrobiology (Reading, England) · 2025Article
- Systematic Determination of the Impact of Structural Edits on Peptide Accumulation into Mycobacteria.ACS chemical biology · 2025Article
- A novel bioactive peptide-peptoid hybrid of alpha-calcitonin gene-related peptide protects against pressure-overload induced heart failure.Frontiers in pharmacology · 2025Article
- Antimicrobial Peptides as Immunomodulators and Antimycobacterial Agents to Combat Mycobacterium tuberculosis: a Critical Review.Probiotics and antimicrobial proteins · 2023Review
- Review: Structure-Activity Relationship of Antimicrobial Peptoids.Pharmaceutics · 2023Review
- Structure-activity relationships of antibacterial peptides.Microbial biotechnology · 2023Review
- Membrane-acting biomimetic peptoids against visceral leishmaniasis.FEBS open bio · 2023Article
- Review
- Article
- Efficacy of Cathelicidin-Mimetic Antimicrobial Peptoids against Staphylococcus aureus.Microbiology spectrum · 2022Article
- Role of Antimicrobial Peptides in Treatment and Prevention of Mycobacterium Tuberculosis: A Review.International journal of peptide research and therapeutics · 2022Review
- Antimicrobial Peptide Mimics for Clinical Use: Does Size Matter?Frontiers in immunology · 2022Review
- Anti-mycobacterial activity evaluation of designed peptides: cryptic and database filtering based approach.Archives of microbiology · 2021Article
- Antimicrobial Peptides as Potential Anti-Tubercular Leads: A Concise Review.Pharmaceuticals (Basel, Switzerland) · 2021Review
- Potent Antiviral Activity against HSV-1 and SARS-CoV-2 by Antimicrobial Peptoids.Pharmaceuticals (Basel, Switzerland) · 2021Article
- Assessment of in vitro activities of novel modified antimicrobial peptides against clarithromycin resistant Mycobacterium abscessus.PloS one · 2021Article
- Identification and Characterization of Two Defensins from Capsicum annuum Fruits that Exhibit Antimicrobial Activity.Probiotics and antimicrobial proteins · 2020Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
Abstract
Tuberculosis is a leading cause of death worldwide. Resistance of Mycobacterium to antibiotics can make treatments less effective in some cases. We tested selected oligopeptoids--previously reported as mimics of natural host defense peptides--for activity against Mycobacterium tuberculosis and assessed their cytotoxicity. A tetrameric, alkylated, cationic peptoid (1-C13(4mer)) was most potent against M. tuberculosis and least cytotoxic, whereas an unalkylated analogue, peptoid 1(4mer), was inactive. Peptoid 1-C13(4mer) thus merits further study as a potential antituberculosis drug.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.